Acquisition momentum Centricity Research recently expanded its network by acquiring Lucas Research, signaling growth capacity, enhanced therapeutic reach, and potential for cross-sell of CRO services across a broader client base.

Leadership stability New leadership appointments including a CEO and CFO in 2023 indicate a strategic shift and investor confidence, presenting an opening to discuss governance, financial partnerships, and scalable pricing or expansion models.

Financial footing With reported revenue in the several hundred million range and ongoing growth initiatives supported by Trinity Hunt, there is an opportunity to position premium CRO offerings, risk-sharing arrangements, and multi-site trial capabilities to mid- to large-sized sponsors.

Scaleable footprint Over 40 integrated clinical research offices across North America provide a nationwide footprint for fast-start Phase I-IV trials, enabling sponsorships seeking site diversification, patient access, and reduced cycle times.

Diverse capabilities Active in over 35 therapeutic areas and experience with pharmaceutical, biotechnology, and medical device trials open doors for cross-therapy programs, adjunct studies, and expanded regulatory-compliance services to diverse sponsors.